Participating in ASPREE
Thank you to all our 19,114 ASPREE participants enrolled in the ASPREE study in Australia and the USA. The ASPREE clinical trial formally concluded in January 2018.
- Participating in the ASPREE study involved taking your study tablet every day (up until June 2017), attending annual health checks and receiving brief phone calls (until January 2018).
- ASPREE is a double-blinded, placebo controlled study, which means researchers, GPs and participants did not know whether your tablet was 100 mg of aspirin or a matched placebo tablet.
- Our team called you approximately every three months between annual study visits, asking about your health.
- Many participants also enrolled in ASPREE sub-studies. Thank you! Your willingness to share health information and/or undergo additional clinical measurements such as an MRI, is much appreciated.
- ASPREE-Hearing, ASPREE-AMD and ACES (ASPREE Cancer Endpoint Study) sub studies are ongoing.
- Participants were notified of their assigned ASPREE study tablet around the same time as publication of the main study results in September 2018.
Participating in ASPREE-XT
Our sincere thanks to ASPREE participants who have enrolled in the follow-up observational study, ASPREE-XT (eXTension), in Australia and the USA. The ASPREE-XT study commenced in January 2018.
- Participating in the ASPREE study involves attending annual health checks in the same locations as ASPREE, and your consent to access your health information.
- Our team will call you approximately every six months between annual study visits, asking about your health.
- There are no study tablets to take or fasting blood tests in ASPREE-XT.
- It doesn’t matter which study tablet you took during ASPREE, or for how long, your contribution to ASPREE-XT is important.
- It’s not too late to enrol in ASPREE-XT.